{"doc_id": "33568628", "type of study": "Therapy", "title": "", "abstract": "Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.\nTreatment of severe Coronavirus Disease 2019 (COVID-19) is challenging.\nWe performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage, based on our phase 1 data.\nIn this randomized, double-blind, and placebo-controlled trial, we recruited 101 severe COVID-19 patients with lung damage.\nThey were randomly assigned at a 2:1 ratio to receive either UC-MSCs (4\u2009\u00d7\u2009107 cells per infusion) or placebo on day 0, 3, and 6.\nThe primary endpoint was an altered proportion of whole lung lesion volumes from baseline to day 28.\nOther imaging outcomes, 6-minute walk test (6-MWT), maximum vital capacity, diffusing capacity, and adverse events were recorded and analyzed.\nIn all, 100 COVID-19 patients were finally received either UC-MSCs (n\u2009=\u200965) or placebo (n\u2009=\u200935).\nUC-MSCs administration exerted numerical improvement in whole lung lesion volume from baseline to day 28 compared with the placebo (the median difference was -13.31%, 95% CI -29.14%, 2.13%, P\u2009=\u20090.080).\nUC-MSCs significantly reduced the proportions of solid component lesion volume compared with the placebo (median difference: -15.45%; 95% CI -30.82%, -0.39%; P\u2009=\u20090.043).\nThe 6-MWT showed an increased distance in patients treated with UC-MSCs (difference: 27.00\u2009m; 95% CI 0.00, 57.00; P\u2009=\u20090.057).\nThe incidence of adverse events was similar in the two groups.\nThese results suggest that UC-MSCs treatment is a safe and potentially effective therapeutic approach for COVID-19 patients with lung damage.\nA phase 3 trial is required to evaluate effects on reducing mortality and preventing long-term pulmonary disability. (Funded by The National Key R&D Program of China and others.\nClinicalTrials.gov number, NCT04288102.\n", "Evidence Map": {"Enrollment": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 95}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 131, "end": 146}, {"term": "lung damage", "negation": "affirmed", "UMLS": {}, "start": 161, "end": 172}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 99}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 21}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 114}, {"term": "lung damage", "negation": "affirmed", "UMLS": {}, "start": 129, "end": 140}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients : a randomized , double-blind , placebo-controlled phase 2 trial .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 95}], "Intervention": [{"term": "human umbilical cord-derived mesenchymal stem cells", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 61, "has_relation": "N/A"}], "Outcome": [{"term": "lung damage", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 76}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Treatment of severe Coronavirus Disease 2019 ( COVID-19 ) is challenging .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-mesenchymal stem cells ( UC-MSCs ) to treat severe COVID-19 patients with lung damage , based on our phase 1 data .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 131, "end": 146}, {"term": "lung damage", "negation": "affirmed", "UMLS": {}, "start": 161, "end": 172}], "Intervention": [{"term": "human umbilical cord-mesenchymal stem cells ( UC-MSCs )", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 121, "has_relation": "N/A"}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 51}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 62}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "In this randomized , double-blind , and placebo-controlled trial , we recruited 101 severe COVID-19 patients with lung damage .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 99}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "They were randomly assigned at a 2:1 ratio to receive either UC-MSCs ( 4 \u00d7 107 cells per infusion ) or placebo on day 0 , 3 , and 6 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "UC-MSCs", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 68, "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 103, "end": 110, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The primary endpoint was an altered proportion of whole lung lesion volumes from baseline to day 28 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "proportion of whole lung lesion volumes", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 75}], "Observation": [{"term": "altered", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 35}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Other imaging outcomes , 6-minute walk test ( 6-MWT ) , maximum vital capacity , diffusing capacity , and adverse events were recorded and analyzed .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "imaging outcomes", "negation": "affirmed", "UMLS": {}, "start": 6, "end": 22}, {"term": "6-minute walk test ( 6-MWT )", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 53}, {"term": "maximum vital capacity", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 78}, {"term": "diffusing capacity", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 99}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "In all , 100 COVID-19 patients were finally received either UC-MSCs ( n = 65 ) or placebo ( n = 35 ) .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 21}], "Intervention": [{"term": "UC-MSCs", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 67, "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 89, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "UC-MSCs administration exerted numerical improvement in whole lung lesion volume from baseline to day 28 compared with the placebo ( the median difference was -13.31 % , 95 % CI-29.14 % , 2.13 % , P=0.080 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "UC-MSCs", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 7, "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 123, "end": 130, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "whole lung lesion volume", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 80}, {"term": "median difference", "negation": "affirmed", "UMLS": {}, "start": 137, "end": 154}], "Observation": [{"term": "numerical improvement", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 52}, {"term": "-13.31 %", "negation": "affirmed", "UMLS": {}, "start": 159, "end": 167}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "UC-MSCs", "has_relation": "N/A"}, "Observation": "numerical improvement", "Outcome": "whole lung lesion volume", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "numerical improvement", "Outcome": "whole lung lesion volume", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "UC-MSCs significantly reduced the proportions of solid component lesion volume compared with the placebo ( median difference : -15.45 % ; 95 % CI -30.82 % , -0.39 % ; P = 0.043 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "UC-MSCs", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 7, "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 104, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "proportions of solid component lesion volume", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 78}], "Observation": [{"term": "significantly reduced", "negation": "affirmed", "UMLS": {}, "start": 8, "end": 29}, {"term": "%", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 135}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The 6-MWT showed an increased distance in patients treated with UC-MSCs ( difference : 27.00 m ; 95 % CI 0.00 , 57.00 ; P = 0.057 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "UC-MSCs", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 71, "has_relation": "N/A"}], "Outcome": [{"term": "6-MWT", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 9}, {"term": "distance", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 38}], "Observation": [{"term": "increased", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 29}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The incidence of adverse events was similar in the two groups .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "two groups", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 61, "has_relation": "N/A"}], "Outcome": [{"term": "incidence of adverse events", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 31}], "Observation": [{"term": "similar", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 43}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "two groups", "has_relation": "N/A"}], "Observation": "similar", "Outcome": "incidence of adverse events", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "These results suggest that UC-MSCs treatment is a safe and potentially effective therapeutic approach for COVID-19 patients with lung damage .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 114}, {"term": "lung damage", "negation": "affirmed", "UMLS": {}, "start": 129, "end": 140}], "Intervention": [{"term": "UC-MSCs", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 34, "has_relation": "N/A"}], "Outcome": [], "Observation": [{"term": "safe", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 54}, {"term": "effective", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 80}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "A phase 3 trial is required to evaluate effects on reducing mortality and preventing long-term pulmonary disability . ( Funded by The National Key R&D Program of China and others .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "ClinicalTrials.gov number , NCT04288102 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}